These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 10498663)

  • 1. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
    Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N
    Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability of serologic response after lamivudine treatment of chronic hepatitis B.
    Dienstag JL; Cianciara J; Karayalcin S; Kowdley KV; Willems B; Plisek S; Woessner M; Gardner S; Schiff E
    Hepatology; 2003 Apr; 37(4):748-55. PubMed ID: 12668966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.
    Song BC; Suh DJ; Lee HC; Chung YH; Lee YS
    Hepatology; 2000 Oct; 32(4 Pt 1):803-6. PubMed ID: 11003626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.
    Fung J; Lai CL; Tanaka Y; Mizokami M; Yuen J; Wong DK; Yuen MF
    Am J Gastroenterol; 2009 Aug; 104(8):1940-6; quiz 1947. PubMed ID: 19455108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg responses.
    Jang JW; Bae SH; Choi JY; Kim CW; Han NI; Han JY; Choi SW; Yoon SK; Chung KW; Sun HS
    J Gastroenterol Hepatol; 2006 Feb; 21(2):384-91. PubMed ID: 16509863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
    Yao G; Cui Z; Wang B; Yao J; Zeng M
    Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term therapy of chronic hepatitis B with lamivudine.
    Lau DT; Khokhar MF; Doo E; Ghany MG; Herion D; Park Y; Kleiner DE; Schmid P; Condreay LD; Gauthier J; Kuhns MC; Liang TJ; Hoofnagle JH
    Hepatology; 2000 Oct; 32(4 Pt 1):828-34. PubMed ID: 11003630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine as initial treatment for chronic hepatitis B in the United States.
    Dienstag JL; Schiff ER; Wright TL; Perrillo RP; Hann HW; Goodman Z; Crowther L; Condreay LD; Woessner M; Rubin M; Brown NA
    N Engl J Med; 1999 Oct; 341(17):1256-63. PubMed ID: 10528035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon.
    Hartman C; Berkowitz D; Shouval D; Eshach-Adiv O; Hino B; Rimon N; Satinger I; Kra-Oz T; Daudi N; Shamir R
    Pediatr Infect Dis J; 2003 Mar; 22(3):224-9. PubMed ID: 12634582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
    Sarin SK; Sandhu BS; Sharma BC; Jain M; Singh J; Malhotra V
    J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
    Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
    J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stopping lamivudine therapy after biochemical breakthrough may be a feasible option in selected HBeAg-positive patients.
    Jang JW; Choi JY; Bae SH; Yoon SK; Kim CW; Nam SW; Lee CD; Lee YS; Cha SB; Chung KW
    J Med Virol; 2005 Nov; 77(3):367-73. PubMed ID: 16173025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M; Xu B; Yao GB
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
    Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
    Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants for sustained HBeAg response to lamivudine therapy.
    Chien RN; Yeh CT; Tsai SL; Chu CM; Liaw YF
    Hepatology; 2003 Nov; 38(5):1267-73. PubMed ID: 14578866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.